InsidersTradesSigma
基于 5 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
Discover the detailed record of transactions filed by Chambers Michael Andrew, 董事. Officer active across 1 company, notably Sarepta Therapeutics, Inc.. Aggregated, 11 reports have been published. Split: 6 buys · 0 sell. Total volume traded: €11.2m. Activity tracked since 2 June 2022. The latest transaction was disclosed on 16 August 2024 (Acquisition). Regulator: SEC (Form 4). All data is openly available.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
11 条申报中的 11 条
Michael Andrew Chambers is a Board Member at Sarepta Therapeutics, Inc., a biopharmaceutical company focused on developing treatments for rare diseases. As a board member, he participates in overseeing the company's strategies and making key decisions. Michael brings expertise in biopharmacy and product development.